The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Optimizing transplant outcomes in patients allografted for AML
Jeffrey Lancet
Charles Craddock
Naval Daver
Jorge Sierra
Selina Luger
Gail J. RobozDuring the AML Hub Steering Committee meeting held on May 17, 2023, Charles Craddock chaired a discussion on optimizing transplant outcomes in patients allografted for acute myeloid leukemia, with contributions from Gail Roboz, Selina Luger, Jorge Sierra, Naval Daver, and Jeffrey Lancet.
Optimizing transplant outcomes in patients allografted for AML
Craddock discusses the optimal selection of patients for transplant and strategies to improve outcomes in patients who are candidates for transplant, with a particular focus on conditioning regimens. He highlights the US-CTN 0901 study comparing myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) regimens and the FIGARO trial assessing intensified RIC regimens. The committee discusses the timing and selection of patients for transplant and the difference in patients’ and clinicians’ perceptions of the chance of a cure. They also discuss the need for randomized trials assessing transplantation and factors that affect transplant outcomes, the optimal design of these trials, and the value of data sharing between centers. They raise the need for the standardization of the status of patients going to transplant.
